DISHMAN

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of Notice of court Convened Meeting of equity shareholders, secured Creditors and Un-Secured Creditors of the Company

DISHMAN:The Exchange had sought clarification from the Company with respect to announcement dated May 19, 2016, regarding Outcome of Board Meeting held on May 19, 2016.The reply of the Company is attached.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding "Transcript of Conference Call".

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that Ms. Shrima G. Dave, Asst. Company Secretary of the Company is designated as Compliance Officer of the Company w.e.f. May 21, 2016 in place of Ms. Pinaz H. Pithadia.

DISHMAN:The Exchange has sought clarification from Dishman Pharmaceuticals and Chemicals Limited with respect to announcement dated 19-May-2016, regarding " Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 19, 2016."On basis of above the Company is required to clarify following:1. The amount and percentage of the turnover or revenue or income and net worth contributed by such subsidiary of the listed entity during the last financial year;2. Date on which the agreement for sale has been entered into;3. The expected date of co

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of Investor Presentation on financial result for the quarter and year ended March 31, 2016 made to Analyst and Investors.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Intimation of Conference Call.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the company has arranged Conference Call with investors on May 20, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 19, 2016.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of Form A for the Financial Year 2015-2016 as per Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the standalone & consolidated financial results for the period ended March 31, 2016.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of Minutes of proceedings of Declaration of Result of Postal Ballot held on April 21, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Management Committee of Board of Directors of the Company vide resolution passed in their meeting held on May 5, 2016, have approved the issue and allotment of 8,06,97,136 equity shares of Rs.2/- each, as fully paid-up bonus shares in the ratio of 1 (one) equity share for every 1 (one) equity share held to those shareholders whose names appear in the Register of Members / List of Beneficial owners as on the Record Date i.e. on May 3, 2016.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of the Certified True Copy of Resolutions passed through Postal Ballot.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company has fixed Record Date as May 3, 2016 for the purpose of deciding the members who shall be eligible for allotment of the Bonus shares in the proportion of 1 (One) Bonus Equity Share of Rs.2/- (Rupees Two only) each, for every 1 (One) fully paid up Equity Share of Rs.2/- (Rupees Two only) each.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window shall remain closed from April 22, 2016 to May 21, 2016 (both days inclusive) for all the connected persons.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the details of voting results of the Postal Ballot along with Report of Scrutinizer pursuant to Regulation 44(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Janmejay R. Vyas has submitted to the Exchange vide letter dated April 2, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company has acquired further 50% stake in Schutz Dishman Biotech Ltd., a Joint Venture Indian Company, from the existing JV Partner i.e. SCHUTZ & CO. BETEILIGUNGSGESELLSCHAFT MBH, Germany for a consideration of EURO 300,000.Schutz Dishman Biotech Ltd. ("Schutz Dishman"), is engaged in the business of manufacturing of Bulk Drugs, Drug formulations and performance Chemicals in India for export markets. Its plant is USFDA approved and is located in the existing campus of Dishman's Bavla manufacturing facility. The sa

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of the notice published in the newspaper regarding Postal Ballot Notice, Pursuant to Section 110 of the Companies Act, 2013.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of the Postal Ballot Notice, Pursuant to Section 110 of the Companies Act, 2013 read with the Companies ( Management and Administration) Rules, 2014.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange the Cut off date for Postal Ballot as March 11, 2016 for the purpose of voting on postal ballot for both electronically and voting through ballot paper.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company proposes to conduct postal ballot for obtaining the approval of members of the Company for bonus issue of equity shares as decided in the board meeting on February 24, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the board has declared an interim dividend of Rs. 2.00(i.e @ of 100%) per equity share on 8,06,97,136 equity shares of Rs. 2.00 each of the Company for the financial year 2015-16. The interim dividend shall be paid to the members entitled thereto, on and from March 22, 2016. The Dividend cheques/warrants would be posted on or after March 22, 2016 and within 30days from the date of declaration of interim dividend as provided in the Companies Act, 2013.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company has fixed Record Date as March 18, 2016 for the purpose of Payment of Interim dividend for the financial year 2015-16, if declared by the Board of Directors of the Company.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain closed from March 05, 2016 to March 13, 2016 (both days inclusive) for all the connected persons.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company are submitting herewith the Ratings revised by India Rating and Research Pvt. Ltd., to Positive from Stable for Long Term/fund based facilities and Non-Convertible Debenture issued (listed debt instruments) by the Company.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that Mr Tushar D Shah has resigned from the post of Company Secretary & Compliance Officer of the Company and his resignation has been accepted with effect from the close of normal office hours on February 25, 2016.Ms. Pinaz H Pithadia, Asst. Company Secretary of the Company is designated as Compliance Officer of the Company w.e.f. February 26, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 24, 2016 has considered and recommended a bonus issue of equity shares in the ratio of 1 (one) equity share for every 1(one) equity share held, as on record date to be determined by the board.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange about the outcome of the board meeting held on February 24, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Earnings Conference Call Transcript for quarter and nine months ended December 31, 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding a presentation on "Q3 & 9M FY16 Results Update."

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company has arranged Conference Call with Investors on February 08, 2016 to discuss the financial result and performance of the Company for the quarter ended December 31, 2015.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the consolidated financial results along with the Limited Review Report for the period ended December 31, 2015.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended December 31, 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the trading window for the Designated Employees of the Company shall remain closed from 1st February, 2016 to 7th February, 2016 (both days inclusive). During this period, Directors, Designated Employees and their dependents are required not to deal in the shares of the Company.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange vide letter dated January 28, 2016 regarding a press release titled "Dishman Netherlands awarded for its Corporate Social Responsibility".

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding the Intimation of Analyst /Institutional Investors Meeting held Under SEBI (LODR) Regulation , 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company has appointed Dr. Himani Dhotre, most experience Chemist as CEO for its Bavla Plant.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange the details of the authorised persons for the purpose of determining the materiality of any event or transaction or information and for the purpose of making disclosure to Stock Exchange pursuant to Regulation 30(5) of the SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015.

The Exchange has sought clarification from Dishman Pharmaceuticals and Chemicals Limited with respect to recent news item captioned "USFDA gives Warning Letter to Dishman due to Clovis issues." The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Dishman Pharmaceuticals and Chemicals Limited has submitted their response.

The Exchange has sought clarification from Dishman Pharmaceuticals and Chemicals Limited, with respect to recent news item captioned "USFDA gives Warning Letter to Dishman due to Clovis issues". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-Sep-2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding the Proceedings of Annual General Meeting held on September 29, 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the trading window for the Designated Employees of the Company shall remain close from October 8, 2015 to October 31, 2015 (both days inclusive).

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the September 29, 2015 along with Report of Scrutinizer pursuant to clause 35A of the Listing Agreement.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that "Dishman has been awarded manufacture of SIRTURO (bedaquiline) API".

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of Minutes of Extra Ordinary General Meeting of the Company held on August 14, 2015.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that for the purpose of 32nd Annual General Meeting, the Company will provide the e-voting facility to its members in respect of the businesses to be transacted at 32nd Annual General Meeting schedule to be held on September 29, 2015. Therefore, the Company has fixed September 22, 2015 as cut off date for the purpose of determining the members entitled to vote electronically.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-Jun-2015.